High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis

Digestive and Liver Disease

Volumn 43, Issue 5, 2011, Pages 404-410

  Petta, Salvatore ^a   Tripodo, Claudio ^a   Grimaudo, Stefania ^a   Cabibi, Daniela ^a   Cammà, Calogero ^a   Di Cristina, Antonietta ^a   Di Marco, Vito ^a   Di Vita, Gaetano ^a   Ingrao, Sabrina ^a   Mazzola, Alessandra ^a   Marchesini, Giulio ^b   Pipitone, Rosaria ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HCV; NASH; RBP4; Steatosis

Indexed keywords

RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; CHOLECYSTECTOMY; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER FIBROSIS; LIVER INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; WESTERN BLOTTING;

ADULT; AGE FACTORS; BODY MASS INDEX; FATTY LIVER; FIBROSIS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; RETINOL-BINDING PROTEINS, PLASMA; RNA, MESSENGER; WAIST CIRCUMFERENCE;

EID: 79953271176     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.12.013     Document Type: Article

References (39)

1. Bugianesi E., Marchesini G., Gentilcore E., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006, 44:1648-1655.
2. van der Poorten D., Milner K.L., Hui J., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48:449-457.
3. Petta S., Cammà C., Di Marco V., et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008, 103:1136-1144.
4. Cammà C., Bruno S., Di Marco V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006, 43:64-71.
5. Lonardo A., Adinolfi L.E., Petta S., et al. Hepatitis C and diabetes: the inevitable coincidence?. Expert Rev Anti Infect Ther 2009, 7:293-308.
6. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
7. Yang Q., Graham T.E., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
8. Graham T.E., Yang Q., Bluher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2263-2552.
9. von Eynatten M., Lepper P.M., Liu D., et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007, 50:1930-1937.
10. van Dam R.M., Hu F.B. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2?. Clin Chem 2007, 53:5-7.
11. Blaner W.S. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 1989, 10:308-316.
12. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm 2007, 75:1-32.
13. Larter C.Z., Farrell G.C. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?. J Hepatol 2006, 44:253-261.
14. Hellemans K., Verbuyst P., Quartier E., et al. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 2004, 39:97-108.
15. Yagmur E., Weiskirchen R., Gressner A.M. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007, 30:1168-1172.
16. Bahr M.J., Boeker K.H., Manns M.P., et al. Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Clin Endocrinol (Oxf) 2009, 70:60-65.
17. Wu H., Jia W., Bao Y., et al. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 79:185-190.
18. Seo J.A., Kim N.H., Park S.Y., et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2009, 68:555-560.
19. Petta S., Cammà C., Di Marco V., et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology 2008, 48:28-37.
20. Stefan N., Hennige A.M., Staiger H., et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007, 30:1173-1178.
21. Milner K.L., van der Poorten D., Xu A., et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009, 49:1926-1934.
22. Schina M., Koskinas J., Tiniakos D., et al. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res 2009, 39:972-978.
23. Nobili V., Alkhouri N., Alisi A., et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:575-579.
24. Alkhouri N., Lopez R., Berk M., et al. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009, 43:985-989.
25. Iwasa M., Hara N., Miyachi H., et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 2009, 16:716-723.
26. Huang J.F., Dai C.Y., Yu M.L., et al. Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. J Hepatol 2009, 50:471-478.
27. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
28. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 411:313-321.
29. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991, 13:372-374.
30. Bellovino D., Apreda M., Gragnoli S., et al. Vitamin A transport: in vitro models for the study of RBP secretion. Mol Asp Med 2003, 24:411-420.
31. Selvaraj S.R., Bhatia V., Tatu U. Oxidative folding and assembly with transthyretin are sequential events in the biogenesis of retinol binding protein in the endoplasmic reticulum. Mol Biol Cell 2008, 19:5579-5592.
32. Kasai D., Adachi T., Deng L., et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 2009, 50:883-894.
33. Fisher C.D., Lickteig A.J., Augustine L.M., et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 2009, 613:119-127.
34. Lickteig A.J., Fisher C.D., Augustine L.M., et al. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 2007, 35:1970-1978.
35. Khu Y.L., Tan Y.J., Lim S.G., et al. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J 2004, 384:401-409.
36. Osna N.A., White R.L., Krutik V.M., et al. Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress. Gastroenterology 2008, 134:2144-2152.
37. Strnad P., Zatloukal K., Stumptner C., et al. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta 2008, 1782:764-774.
38. Tsutsumi T., Suzuki T., Shimoike T., et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002, 35:937-946.
39. Ost A., Danielsson A., Lideón M., et al. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J 2007, 21:3696-3704.